Jaguar Animal Health Inc. ( (JAGX) ) has released its Q1 earnings. Here is a breakdown of the information Jaguar Animal Health Inc. presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jaguar Health, Inc. is a pharmaceutical company specializing in the development of plant-based prescription medicines for both humans and animals, focusing on gastrointestinal health and conditions. The company is known for its sustainable practices in sourcing ingredients from rainforest areas.
In the first quarter of 2025, Jaguar Health reported a decrease in net revenue to approximately $2.2 million, down 6% from the same period in 2024 and 37% from the previous quarter. Despite this decline, the company saw a slight increase in Mytesi prescription volume compared to the first quarter of 2024.
Key financial metrics highlighted in the report include a net loss of $10.4 million, an increase from the previous year’s first quarter. The company also reported a rise in sales and marketing expenses due to expanded market access activities and the launch of Gelclair. Research and development expenses decreased following the conclusion of a major clinical trial.
Looking ahead, Jaguar Health is focused on advancing its pipeline, with upcoming meetings with the FDA and additional proof-of-concept results expected throughout the year. The company remains committed to its mission of developing innovative treatments for gastrointestinal conditions.